Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1990 1
1991 2
1992 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Barucainide, a novel class Ib antiarrhythmic agent with a slow kinetic property: electrophysiologic observations in isolated canine and rabbit cardiac muscle.
Takanaka C, Singh BN. Takanaka C, et al. Am Heart J. 1990 May;119(5):1050-60. doi: 10.1016/s0002-8703(05)80234-0. Am Heart J. 1990. PMID: 2330863
Barucainide produced marked shortening of the action potential duration (APD), which indicates that barucainide exerts class Ib antiarrhythmic effects. Such shortening effects on the APD were not affected by pretreatment with 1 mmol/L cobalt or with 0.5 mmol/L 4-ami …
Barucainide produced marked shortening of the action potential duration (APD), which indicates that barucainide exerts class I …
Efficacy and tolerance of the new class IB antiarrhythmic barucainide: an intravenous dose-finding study.
Zehender M, Meinertz T, Hohnloser S, Geibel A, Just H. Zehender M, et al. Clin Pharmacol Ther. 1991 Jan;49(1):78-85. doi: 10.1038/clpt.1991.13. Clin Pharmacol Ther. 1991. PMID: 1988242
Barucainide is a new class IB antiarrhythmic agent that was studied for efficacy and safety after intravenous administration in patients with severe ventricular arrhythmias. All patients received 80 mg/hr barucainide intravenously for 7 hours or until ventricular ar …
Barucainide is a new class IB antiarrhythmic agent that was studied for efficacy and safety after intravenous administration in patie …
[Effect of barucainide on left ventricular ejection fraction in patients with ventricular cardiac arrhythmias].
Scheininger M, Dziersk J, Kullak W, Kors A, Köhler JA, Theisen K. Scheininger M, et al. Z Kardiol. 1991 Oct;80(10):630-6. Z Kardiol. 1991. PMID: 1722935 Clinical Trial. German.
Mean left-ventricular ejection fraction was 37.6%, ranging from 18% to 58%. Therapy with barucainide (300-400 mg/day) resulted in a significant reduction of ventricular arrhythmias in 7 of 10 patients; in one patient barucainide had a clear proarrhythmic effect. ... …
Mean left-ventricular ejection fraction was 37.6%, ranging from 18% to 58%. Therapy with barucainide (300-400 mg/day) resulted in a s …
[The effectiveness of barucainide in supraventriculr and ventricular arrhythmias].
Brugger P. Brugger P. Z Kardiol. 1989 Aug;78(8):510-8. Z Kardiol. 1989. PMID: 2477959 Clinical Trial. German.
The anti-arrhythmic efficacy of barucainide, a new class IB anti-arrhythmic agent, was evaluated in an open-label therapeutic study in a total of 15 patients with coronary artery disease. ...Ventricular tachycardia present in 4 of 15 patients was suppressed in all cases. …
The anti-arrhythmic efficacy of barucainide, a new class IB anti-arrhythmic agent, was evaluated in an open-label therapeutic study i …
Investigation of the pharmacokinetic behavior of barucainide in man during an early phase I study.
Brode E, Müller-Peltzer H, Indest H. Brode E, et al. Methods Find Exp Clin Pharmacol. 1992 Nov;14(9):717-24. Methods Find Exp Clin Pharmacol. 1992. PMID: 1294860 Clinical Trial.
The pharmacokinetic behavior of the class Ib antiarrhythmic drug barucainide was investigated in a phase I study in a group of 6 healthy male volunteers after oral administration of an initial single dose of 20 mg and incremental doses between 30 and 70 mg barucainide …
The pharmacokinetic behavior of the class Ib antiarrhythmic drug barucainide was investigated in a phase I study in a group of 6 heal …
[Experimental and initial clinical experiences with the new class Ib anti-arrhythmia agent barucainide].
Gülker H, Heuer H, Frenking B, Haverkamp W, Hindricks G, Bozek B, Bremkes C, Asche KD, Witthöft D. Gülker H, et al. Z Kardiol. 1988 Sep;77(9):587-94. Z Kardiol. 1988. PMID: 2461620 German.
Barucainide is a new class Ib-antiarrhythmic compound which causes a reduction of the upstroke velocity and shortens the duration of the action potential in a dose-dependent fashion. ...In a standardized animal model of ventricular arrhythmia, barucainide proved to …
Barucainide is a new class Ib-antiarrhythmic compound which causes a reduction of the upstroke velocity and shortens the duration of …